Publiziert in: Marktpuls, Unternehmen
Frei
Roche: Chugai: Piasky (crovalimab) for Paroxysmal Nocturnal Hemoglobinuria approved in Japan Dienstag, 26. März 2024 - 18:02
| Investor Update |  |
Chugai: Piasky (crovalimab) for Paroxysmal Nocturnal Hemoglobinuria approved in Japan
Dear Investor,
Please find attached a press release by Chugai:
https://www.roche.com/240326_Chugai_ePiasky_EN.pdf
Do not hesitate to contact us for any further questions.
With best regards,
Roche Investor Relations |
|
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com
| Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
|
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
|
|
|
|
Investor Relations North America |
|
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
|
All rights reserved ©2024 F. Hoffmann-La Roche Ltd.
Group Communications, Grenzacherstrasse 124, CH-4070 Basel, Switzerland